SUMMARY Prior to starting gold treatment 30 patients with rheumatoid arthritis had an elevated mean level of circulating immune complexes measured by Clq binding activity. Gold treatment led to an improvement in disease reflected by significant falls in erythrocyte sedimentation rate (p<O000l), C-reactive protein (p<001), Ritchie articular index (p<0001), and duration of morning stiffness (p<0 05). Concurrently immune complex levels fell, and this change first reached significance after 3 months' treatment (p<005). Serum Clq binding activity was not related to clinical and laboratory measurements of joint inflammation. This suggested to us that there is no direct immunopathological relationship between circulating immune complexes and joint inflammation in rheumatoid arthritis. Serum Clq binding activity was strongly related to IgM-RF levels measured as latex titre (r = 0 7, p<0 001). Removal of immune complexes from serum with Sepharose 4B-staph A (staphylococcal protein A) led to a fall in IgM-RF from 2 mg/ml (2 gll) to 0 4 mg/ml (0.4 g/l). This suggests that the reason-for the relationship between Clq BA and IgM-RF is that, on average, 80 % of serum IgM-RF exists as part of immune complexes containing IgG.
Numerous studies have documented the presence of raised levels of immune complexes in patients with rheumatoid arthritis, and some authors have suggested that they may be related to the aetiology of the disease.' Fewer investigations have been made into the change in levels of immune complexes during effective treatment of rheumatoid arthritis. This might be expected to yield useful information on the temporal relationship between changes in immune complex levels and joint inflammation. If immune complexes are aetiologically related to joint inflammation, circulating levels might be expected to fall prior to or at the same time as improvement in joint inflammation. It also seemed to us that the period following initiation of gold therapy in which disease activity was changing most rapidly would be a particularly good time in which to study the relationship between clinical and serological measurement of disease activity and levels of circulating immune complexes.
Accepted for publication 16 (Fig. 1) . However, the level at 4 months was not significantly different from the initial value. Levels were more consistently lowered from 5 months onwards, but even then the levels at 7 and 9 months were not significantly lower than initial values.
This reflects the rather small quantitative change in immune complex levels and the fact that they plateau at levels at the limit of significance. This pattern differs from the steeper and more sustained falls in RI and CRP. The fall in these measurements first reached significance at 2 and 3 months respectively. After this they fell further and reached a plateau at levels consistently significantly different from their starting values (p<0001 at 4 months for both measurements). These differences are clearly seen in Fig. 1 . Table 1 shows the correlation between measurements which showed significant falls during treatment as well as latex titre. In general, these correlations fell into 2 groups. The first group consisted of serologic and clinical measurements reflecting joint inflammation, namely, ESR, CRP, RI, and DMS. ESR and CRP were strongly related and both correlate with the clinical measurements to a similar degree.
CORRELATIONS BETWEEN DISEASE MEASUREMENTS
The second group consisted of Clq BA and latex titre. These 2 measurements were strongly related (r = 0 7, p<0 001). Latex titre correlated with DMS (r = 0-41, p<0-001), but Clq BA was only weakly related to measurements of disease activity (Table 1) .
RELATIONSHIP BETWEEN CIQ BINDING ACTIVITY AND IgM RHEUMATOID FACTOR
In order to study the strong relationship between IgM-RF measured as latex titre and Clq BA we absorbed 14 rheumatoid sera with staph A to remove IgG containing immune complexes. On analysis 6 sera had Clq BA >15% after absorption with Sepharose 4B (46% ± 7 % mean ± SEM). Clq BA fell significantly (p<0-001, paired Student's t test) with staph A absorption to 13-7% ± 3-5% (mean ± SEM) which is within the normal range (Fig. 2) . There was a corresponding 80% fall in the mean level of IgM-RF measured by ELISA from 2 mg/ml to 04 mg/ml (2 to 0-4 g/l) (p<005).
Individual falls varied from 39% to 97% of the control absorbed value. The 8 sera with no immune complexes in control sera showed no significant change in Clq BA or IgM RF (data not shown).
Discussion
We have shown that immune complex levels measured as Clq BA fell significantly as disease activity improved during the early phase of gold treatment. This is in agreement with Nineham et al.8 who also showed a fall in Clq binding immune complexes during gold treatment of rheumatoid arthritis but using a solid-phase technique. Falls in immune complex levels have also been reported during penicillamine therapy9 and during the treatment ofrheumatoid vasculitis with cytotoxic agents.10 It would thus seem that effective treatment of rheumatoid arthritis with 'second-line' agents is associated with a fall in levels of circulating immune complexes.
The fall in levels of immune complexes first becomes significant after there is already evidence of clinical improvement in joint inflammation (RI, Fig. 1 ). The fall in immune complex levels is neither as steep nor as sustained as the falls in RI and CRP, which are generally thought to be good indicators of inflammatory disease activity. These differences favour the concept that circulating immune complex levels are a secondary phenomenon rather than being directly linked to inflammation in joints in rheumatoid arthritis.
If immune complexes were of aetiological significance in the pathogenesis of joint inflammation, one might expect to see a correlation between levels of complexes and clinical and serological measurements of joint inflammation. We did not find evidence for such a relationship ( 
